Biophys. Acta, 1982, 716:188-193.
Biophys. Acta 2019, 1861 (7), 1317-1328. CURRICULUM VITAE Xxxxxxxx Xxxx was born on the 27th of February 1969 in Nigeria. She obtained a bachelor’s degree in Pharmacy from the University of Nigeria Nsukka in 1991. Thereafter, she undertook a one-year internship program at the University of Nigeria Teaching Hospital Enugu in drug dispensing and compounding. Afterward, she did the mandatory one-year National Youth Service at the Essential Drugs division of the Ministry of Health and Social Welfare Port-Harcourt. She then worked as a community Pharmacist in New Life Care Pharmacy Port- Harcourt for two years. In 1997 she obtained a master’s degree in Pharmaceutical Technology (with distinction) from Kings College, London. Her dissertation investigated the effect of oil structure on microemulsion formation and was supervised by Xxxx. Xxxxx Xxxxxxxx. She was awarded the Xxxxxx Laboratories Prize for best student in Pharmaceutical Technology and the College Prize for the best student from all of the Pharmacy Departments three MSc degrees. Thereafter, she joined Juhel Nigeria Limited, a pharmaceutical manufacturing company as a Production Pharmacist. In the year 2000, she was awarded the World Bank Xxxxxx X. XxXxxxxx Fellowship to investigate the Regulation of the Pharmaceutical industry in Nigeria. She worked in the Pharmaceutical industry for 15 years during which she gained experience in various sections including drug formulation, quality assurance, and regulatory affairs. In 2017, she was admitted to a PhD position at Leiden Academic Centre for Drug Research, Leiden University under the supervision of Prof. Xxxx Xxxxxxxx and Xx. Xxxxxxxxx Xxxxxxx. Her project focused on using lipid model membrane systems as a tool to unravel the underlying factors for skin barrier impairment in inflammatory skin diseases. In November 2021, she was employed as Pharmaceutical Scientist, Manufacturing Science and Technology at Xxxxxx laboratories, Weesp, Netherlands LIST OF PUBLICATIONS
Biophys. Acta, 2019; 1861(7): p. 1317-1328. Xxxx, L. E.; Xxxxxx, X. X.; Xxxxxxxx, X. X.; Xxxxxxx, X. X., Barrier Capability of Skin Lipid Models: Effect of Ceramides and Free Fatty Acid Composition, Langmuir, 2019; 26;35(47):15376-15388
Biophys. Acta, 2021; 1863(1): p. 183487-183497.
Biophys. 2019, 52, No. e3.
Biophys. J. 91, 4350–4367 (2006).
Biophys. Acta - Gen. Subj. 2017, 1861 (12), 3096–3108. xxxxx://xxx.xxx/10.1016/j.bbagen.2017.08.025.
Biophys. Acta - Biomembr. 1798, 1876–1885 (2010). 120. Xxxxxx, X., Xxxxxxx-Xxxxxx, X., Xxxxx, G., Xxxxx, F. F., Xxxxxx, X., Xxxxxxxxx, T., Xxxx Xx, T. R. & Moeck, G. Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro. Antimicrob. Agents Chemother. 53, 918–925 (2009). 121. Xxxxxxxx, O., Xxxxxxxx, G., Xxxxxxx, P. M., Xxx Xxxxxxx, F., Xxxxxxx, Y. & Mingeot-Leclercq, M.-P. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. Biochim. Biophys. Acta - Biomembr. 1788, 1832–1840 (2009). 122. Xxxxx, X. X., Xxxxx, X. X. & Xxxxx, X. X. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections. Infect. Dis. Ther. 5, 1–15 (2016). 123. Xxxxxx, X. X., Xxxxxxx, X. X., Xxxxxxx, X. X., Xxxxx, X. X. & Xxxxx, X. X. Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010. Antimicrob. Agents Chemother. 56, 1639–1642 (2012). 124. XxXxx, G. A., Xxxxxxxx, X., Xxxxx, F. F., Xxxxxx, X., Xxxxxxxxx, I., Xxxx Xx, X. & Xxxxx, G. Time– kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Xxxxxxxxx. 63, 1191–1199 (2009). 125. Xxxxxx, X., Xxxxxxxxx, X., Xxxxxxxx, P. & Xxxxxxxxx, P. Moderate-Level Resistance to Glycopeptide LY333328 Mediated by Genes of the vanA and vanB Clusters in Enterococci. Antimicrob. Agents Chemother. 43, 1875–1880 (1999). 126. Xxxxx, X. X., Xxxxx, X., Xxxxx, F. F., Xxxxxx, M. N., Xxxxxxxx, X. X. & Xxxxxx, X. X. Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility. Antimicrob. Agents Chemother. 60, 3174–3177 (2016).
Biophys. J. 2007, 92, 4064. (41) Xxxxx, Xxxxxxxxx X.; Xxxx, P.; Xxxxxxxxxx, X.; Xxxxxxx, Xxxx X.; Xxxxxx, Xxxxxxxxxxx X.; Xxxxxxx, Xxxxxx X. Xxxxxxx. J. 2013, 104, 1116. (42) Xxxxx, B.; Xxxxxx, X. X.; Xxxxxxxxxx, X. X. Mol. Biol. 2005, 345, 1141.
